{"product_id":"pnc-27-10-mg","title":"PNC-27 10 MG","description":"\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003e\u003cstrong\u003ePNC-27\u003c\/strong\u003e is a \u003cstrong\u003e32-amino-acid investigational peptide\u003c\/strong\u003e designed from a portion of the \u003cstrong\u003ep53 tumor suppressor protein\u003c\/strong\u003e linked to a cell-penetrating sequence. It is being studied as a potential \u003cstrong\u003etargeted anti-cancer peptide\u003c\/strong\u003e, but it is \u003cstrong\u003enot FDA-approved\u003c\/strong\u003e, \u003cstrong\u003enot an established cancer treatment\u003c\/strong\u003e, and \u003cstrong\u003ehas not demonstrated safety or efficacy in human clinical trials\u003c\/strong\u003e. Most evidence comes from cell culture and animal research. \u003cspan class=\"\"\u003e\u003c\/span\u003e\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003eWhat is PNC-27 studied for?\u003c\/h3\u003e\n\u003cp\u003eResearchers have investigated PNC-27 primarily for:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eSelective targeting of cancer cells\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eBreast cancer\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eLeukemia\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eMelanoma\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eColon cancer\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePancreatic cancer\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eProstate cancer\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003eOther tumor types that express \u003cstrong\u003eHDM2 (also called MDM2)\u003c\/strong\u003e on their cell membranes. \u003cspan class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eProposed mechanism of action\u003c\/h3\u003e\n\u003cp\u003eUnlike many cancer therapies that attempt to trigger apoptosis (programmed cell death), PNC-27 appears to work differently in preclinical models:\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003eIt binds to \u003cstrong\u003eHDM2\u003c\/strong\u003e proteins found on the membranes of certain cancer cells.\u003c\/li\u003e\n\u003cli\u003eIt forms \u003cstrong\u003epores\u003c\/strong\u003e in the cancer cell membrane.\u003c\/li\u003e\n\u003cli\u003eThe damaged membrane causes rapid \u003cstrong\u003ecell lysis (necrosis)\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNormal cells appear to be much less susceptible because they generally lack membrane-associated HDM2. \u003cspan class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch3\u003eCommon research stacks\u003c\/h3\u003e\n\u003cp\u003eIn laboratory research, investigators have explored PNC-27:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBy itself\u003c\/strong\u003e (most common)\u003c\/li\u003e\n\u003cli\u003eWith \u003cstrong\u003etraditional chemotherapy agents\u003c\/strong\u003e to evaluate possible additive or synergistic effects\u003c\/li\u003e\n\u003cli\u003eAlongside studies of the \u003cstrong\u003ep53\/MDM2 pathway\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCompared with its closely related analog \u003cstrong\u003ePNC-28\u003c\/strong\u003e \u003cspan class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIt's worth noting that many combinations discussed online with peptides such as BPC-157, TB-500, or growth hormone are \u003cstrong\u003especulative\u003c\/strong\u003e and are \u003cstrong\u003enot supported by peer-reviewed evidence\u003c\/strong\u003e for cancer treatment.\u003c\/p\u003e\n\u003ch3\u003eAdvantages researchers are interested in\u003c\/h3\u003e\n\u003cp\u003ePotential advantages suggested by early research include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSelective activity against certain cancer cells\u003c\/li\u003e\n\u003cli\u003eNovel mechanism compared with chemotherapy\u003c\/li\u003e\n\u003cli\u003eMay work independently of some p53 mutations\u003c\/li\u003e\n\u003cli\u003eRapid destruction of susceptible cancer cells in laboratory models \u003cspan class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Frontline Peptides","offers":[{"title":"Default Title","offer_id":50613458993375,"sku":null,"price":70.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0807\/0810\/8511\/files\/PNC-27.png?v=1785368521","url":"https:\/\/frontlinepeptides.net\/products\/pnc-27-10-mg","provider":"Frontline Peptides","version":"1.0","type":"link"}